Loading
A phase 3 trial of Choline C-11 in Prostate cancer, run by Global Isotopes, LLC d/b/a Zevacor Molecular, completed.
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer is a phase 3 interventional study registered as NCT02260817 by Global Isotopes, LLC d/b/a Zevacor Molecular, with 109 participants recorded, started 2014-10 and reaching its primary completion in 2016-06. Interventions recorded: 11C-choline Injection. Conditions recorded: Metastatic Prostate Cancer.
Linked to the drug Choline C-11 because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
109 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2019-12-17), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Sensitivity of 11C Choline PET Imaging Scansprimary | 11C-choline Comparison Study of CT and MR Modalities | 58 | 97.29% | - | - | link |
Shares Choline C-11 and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.